Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C14H10N2O5S2 and a molecular weight of approximately 350.37 g/mol[1][6]. It contains a thiazolidinedione core linked via a furan ring to a benzenesulfonamide moiety. The compound has been cataloged in chemical and drug databases as an experimental agent but does not have an established pharmacological use or approved indication[1][6]. Its mechanism of action and biological targets are not well characterized in the literature; however, it is structurally related to thiazolidinediones—a class known for modulating nuclear receptors such as PPARγ—but there is no direct evidence that this specific molecule acts on those targets. It has been referenced in structural biology resources (e.g., PDB entry "2uzo") but without detailed functional annotation[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-{5-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]furan-2-yl}benzenesulfonamide.